All relevant data are within the paper, its supporting information files and the Lieber Institute's online data browser (see <http://eqtl.brainseq.org>), according to the access criteria set out in the Lieber brainseq consortium. Raw data has recently been released to stable sources such as dbGaP(phs000979.v1.p1) and Synapse.org(syn12299750) and qualified researchers can apply for the data through dbGaP and Synapse.org. Each of these entries have a non-author point of contact, e.g. joint Addiction, Aging, and Mental Health DAC (<JAAMHDAC@mail.nih.gov>).

Background {#sec005}
==========

The large-scale efforts of genome-wide association studies (GWASs) have in recent years discovered hundreds of single-nucleotide polymorphisms (SNPs) associated with common complex disease. The high reproducibility and well-supported causal link to disease means that these risk SNPs represent precious knowledge towards advances in drug development. However, so far, only few examples of actual implementation as drug candidates exist. We believe that the main reason for this is the lack of a precise understanding of how risk SNPs affect genes and, ultimately, druggable targets. Linking risk SNPs with risk genes is of major importance, and currently, this has been of only limited success.

One reason for this is that the vast majority of risk SNPs are non-coding and thus without an immediately obvious culprit gene. Typically, only 10% of GWAS-identified risk SNPs affect the protein sequence directly or through high-linkage disequilibrium (LD) proxies \[[@pone.0217765.ref001]\]. In the search for gene identification, most risk SNPs have been analyzed using eQTL methods, which often cases can link a non-transcribed SNP to the expression of a proximal gene \[[@pone.0217765.ref002]\] \[[@pone.0217765.ref003]\]. The eQTL method has so far identified a functional association for 30--50% of risk SNPs in brain \[[@pone.0217765.ref002], [@pone.0217765.ref004], [@pone.0217765.ref005]\]. In the case of the Schizophrenia (SZ) GWAS original report, 16% of the findings were shown to have brain eQTL effects at the gene level \[[@pone.0217765.ref001]\], but further studies are increasing this number \[[@pone.0217765.ref006], [@pone.0217765.ref007]\]. The current state of the art analysis of GWAS SNPs and all expression features in the transcriptome suggests that over 50% of the GWAS SNPs are associated with transcription \[[@pone.0217765.ref007]\]. Understanding the mechanisms and mediator-genes of these risk-SNPs are of primary importance for translation of the genetic findings. For this reason, we set out to compare allelic expression quantitative trait loci (aeQTL) that serves the same purpose as an eQTL but is based on the allele fraction within each individual, instead of the total expression from both alleles. We use the term aeQTL to designate imbalances in expression due to stoichiometric variation of a specific genomic variation. We combined a computational phasing of genotypes with deep RNA-seq analysis to identify genes with strong imbalance as correlating with proximal heterozygous GWAS-identified risk-SNPs. For investigation of neighboring genes, the use of haplotypes can give us reproducible phase estimates even when LD is low (Figure 1 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}). The concept is illustrated in [Fig 1](#pone.0217765.g001){ref-type="fig"}: In aeQTL, only samples where the gene has heterozygous transcribed SNPs (txSNPs) can have an allele fraction calculated. When heterozygous, the txSNPs function as reporters of allelic transcription from the risk chromosome copy. In this analysis we have used txSNPs within the exons of each gene investigated, and the allele fraction was set relative to the parent 1 phase, based on phasing results. Therefore, if there is a link with a risk-allele that increases gene expression, the allele fraction should attain one of three levels: i) \>0.5 if the txSNP and the risk SNP are in one phase; ii) Close to 0.5 if the risk-SNP is homozygote, iii) \<0.5 if the txSNP and the risk-SNP are in the opposite phase \[[@pone.0217765.ref008]\]. Thus, the allelic imbalance is a more subtle autosomal version of the well-known X-chromosome inactivation process \[[@pone.0217765.ref009]\].

![Comparison of eQTL and aeQTL for *PRMT7* and the *rs8044995* risk-SNP.\
**(A)** In a standard eQTL analysis the X-axis (input variable) is the genotype of the risk-SNP and the Y-axis (response variable) is the expression of the gene. **(B)** aeQTL analysis of the same risk-snp/gene pair. The Y-axis shows the fraction of reads coming from the Parent 1 chromosome in the PRMT7 gene. Only samples with a heterozygous txSNP are included, and in samples with more than one heterozygous txSNP the average fraction is used. The X-axis shows the risk-SNP group: samples that are heterozygote with an A-allele on the Parent 1 chromosome are in group 1, samples that are homozygote (A/A or G/G) are in group 2, and samples with a G-allele on the Parent 1 chromosome are in group 3. The linear regression of these values constitutes the basis of the aeQTL model. The supplementary [S2 File](#pone.0217765.s002){ref-type="supplementary-material"} provides plots for all gene-SNP pairs that are listed in [Table 1](#pone.0217765.t001){ref-type="table"}.](pone.0217765.g001){#pone.0217765.g001}

We here present the results of comparing eQTLs and aeQTLs in a deeply sequenced biobank of brain samples, with the goal of illustrating how allelic imbalance genetics may serve as a possible complement.

Methods {#sec006}
=======

Subjects and biopsies {#sec007}
---------------------

A total of 782 individuals were included in the study. The Post-mortem human brain tissue was obtained by autopsy with informed consent from the legal next of kin (protocol 90-M-0142 approved by the NIMH/NIH Institutional Review Board), in accordance with the declaration of Helsinki. Brain samples were obtained from the dorsolateral pre-frontal cortex (DLPFC) (n = 680). Additionally, from the same individuals, DNA was isolated from cerebellar samples for the purpose of genome-wide genotyping and a set of hippocampal formation tissue (n = 421) was used for replication. The age of the individuals ranged from birth to 97 years of age, although a complementary analysis including pre-natal samples are found in Tables S5 and S6 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}. The ethnicity was primarily Afro-American and Caucasian. The mean post-mortem interval was 33.4±20.1 minutes and the mean RIN-value was 8.1±0.9. Further details are described elsewhere \[[@pone.0217765.ref007]\].

Genotyping and RNA sequencing {#sec008}
-----------------------------

For genotyping, the Illumina Human1M-Duo v3.0, illumina 650K and omniX+ microarrays were used. Data was merged using Plink (1.90beta3). The Shapeit2 software (v2.r790) \[[@pone.0217765.ref010]\] was used for pre-phasing, and impute2 (version 2.3.2) for imputation and phasing, using the 1000genomes phase III reference panel.

For the RNA-sequencing of DLPFC and Hippocampus, the library was prepared either by depletion of rRNAs by RiboZero or by a polyA+ extraction of all fragments containing a poly-A tail. Two samples per lane were used producing an average of 129.8 million paired-end reads per sample (Figure 2 and Table S1 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}. Further data access is available at the Lieber Institute's online data browser (<http://eqtl.brainseq.org>).

Data pre-processing {#sec009}
-------------------

STAR software (2.4.2a) was used to align the RNA-sequencing data to the human genome (assembly GRCh37). This was done both in a non-masked and masked version, where the masked reference genome additionally used the ambiguity nucleotide character N for all SNPs in the UCSC track snps142Common, (assembly GRCh37/hg19). Additional re-alignments with masking of RNA-seq-called SNPs were performed. Samtools mpileup (version 0.1.19) was used to discover the variant-positions in the RNA-seq data (*samtools mpileup---BCF---skip-indels---positions*), and bcftools was used to loosely pre-filter these (*bcftools filter---exclude 'MIN(QUAL)\<10 \| MIN(DP)\<10 \| AC\<10'*). To reduce multiple testing burden the analysis was restricted to include genes only within 200kb from the 108 SZ risk loci, this was motivated by the complex phasing reproducibility pattern shown in Figure 1 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}. The AllelicImbalance package was then used to import relevant read counts at each of the discovered txSNPs \[[@pone.0217765.ref011]\]. The mapped reads were summarized as read counts for each allele type at each txSNP, and their phase information inferred from shapeit2 was added, which made it possible to calculate the phase specific fraction for parent 1. These *AllelicImbalance* data-objects were considered as the pre-processed basis of all further aeQTL analysis.

Filtering, defining of regions and pairing of risk-SNPs {#sec010}
-------------------------------------------------------

On the pre-processed AllelicImbalance objects we further set a threshold of at least 10 reads from each allele for a txSNP and restricted the analysis to exons including the 5' and 3' UTR. We also required that at least 10% of the total expression came from the less expressed allele, to hinder sequencing errors creating false allelic imbalance. All genes or txSNPs having at least 5 usable individuals in at least two genotype groups were used in the regression model. The amount of remaining usable individuals for the analysis can be seen in [Fig 2A and 2B](#pone.0217765.g002){ref-type="fig"}.

![Filtration and mapping bias considerations in analysis pipeline.\
**(A)** Shows the least amount of individuals (Y-axis) for a given amount of txSNPs (X-axis) at different condition levels, namely *Het*, i.e. count of heterozygous SNPs, *Het+filt*, i.e. the count of heterozygous SNPs that pass QC filtration, and *Hom*, i.e. the remaining SNPs, which are homozygous. **(B)** Similar, but instead with an X-axis showing gene-count for which at least one txSNP fulfills the condition level. In other words, the number analyzable individuals for a given amount of the genes of interest. **(C)** The fraction of reference-allele containing reads measured over all txSNPs, dependent on using a masked or a non-masked genome. The horizontal line at 0.5 indicates the expected fraction under the assumption of no mapping bias. Yellow indicates DLPFC tissue, green indicates Hippocampus tissue. **(D)** Number of txSNPs in the genes of interest with at least one heterozygote sample among the 782 analyzed individuals.](pone.0217765.g002){#pone.0217765.g002}

Further, txSNP-regions were defined according to the UCSC RefSeq gene annotation database (version 12-11-2015) in a way that each txSNP-region corresponded to one gene. The only exception was overlapping genes, which were included in the same txSNP-region. Using the phase information, we then summarized all txSNPs in the region to get a single value for each sample.

Analyzing aeQTL through the use of phasing information {#sec011}
------------------------------------------------------

Our method for assessing aeQTLs was inspired by previous work by Almlöf et al, in which expression microarrays were used to obtain allele-specific expression information, and then combined with computationally phased genotypes to link the allele-specific expression with non-transcribed SNPs \[[@pone.0217765.ref008]\]. LD information is correlated, but not outperforming phasing using the 1000Genomes reference panel as illustrated in Figure 1 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}. Two main parts were of importance: Firstly, as with all allelic imbalance based methods, this required the presence of a heterozygous SNP to discern between alleles. To maximize the number of testable genes, summarization of data from *all* txSNPs in a gene (txSNP-region) was therefore used. Secondly, since all genotypes were computationally phased, the relevant allelic imbalance fractions were always calculated in the parent-1-allele direction. Taken together this prompts the *fraction*~*P1*~ variable, which is defined as the number of parent-1 reads divided by reads from both chromosome copies, over all txSNPs in a gene (txSNP-region). Since the non-transcribed risk-SNP is also phased, the association between risk-SNP and the allelic imbalance it creates can be investigated using the linear regression model: $$\text{fraction}_{\text{p1}} \sim \text{risk} - \text{SNP} - \text{group} + \text{covariates}$$

The risk-SNP-group value is enumerated as 0, 1 or 2; being either heterozygote of one phase, e.g. A\|G, homozygote, e.g. A\|A and G\|G, or heterozygote in opposing phase, e.g. G\|A (as illustrated in [Fig 1A](#pone.0217765.g001){ref-type="fig"}, and further detailed in Figure 1 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}). Except when explicitly noted otherwise, we always included the covariates age and sex as well as the first three principal components of the genotyping data and the first ten principal components of the RNA-seq data. To correct for multiple testing we used a FDR 5% threshold, calculated over each risk-SNPs---gene pair (n = 371). For the splicing analysis, we used a separate threshold calculated over each risk-SNPs--txSNPs pair (n = 4032).

Comparable eQTL analysis {#sec012}
------------------------

The eQTL P-values used for comparison are the Lieber- BrainSeq consortium P-values obtainable from this website: <http://eqtl.brainseq.org/>. They are calculated from the same set of human brains, using the same covariates as for the aeQTL analysis, i.e. age, sex, three first genotype principal components and first ten expression principal components. Additionally, we linked comparable measurements from the Lieber BrainSeq consortium's significant eQTL splice evidence for any corresponding aeQTL gene-level evidence.

Results {#sec013}
=======

Pre-processing motivates masked alignment in aeQTL analysis {#sec014}
-----------------------------------------------------------

RNA sequence data from brain tissue for all genes proximal to the known SZ risk-SNPs were scanned for presence of heterozygous transcribed SNPs (txSNPs). In the 493 proximal genes, defined as all genes within 200 kb of the 108 risk loci, a total of 3734 heterozygous txSNPs were found in at least one of the analyzed individuals, illustrated in [Fig 2D](#pone.0217765.g002){ref-type="fig"}. With phasing, these heterozygous txSNPs could function as reporters of transcription from the risk chromosome copy. One set of filters were applied across all txSNPs: this included minimum read-quality, and minimum read-count. Another was applied on basis of each sample: filtration on the minimum expression level and on minimum percent of fraction for each allele. Altogether this left 340 of the 493 proximal genes amendable to analysis using the aeQTL approach ([Fig 2A and 2B](#pone.0217765.g002){ref-type="fig"}). Because of proximity of some risk-SNPs, the 128 risk-SNPs and the 340 genes, created 371 testable pairs of a total of 576 possible SNP-gene pairs in the region.

A potential problem in aeQTL analysis is the propensity for reference genome (ref-allele) allele containing reads to be favored over the alternative allele (alt-allele) during the alignment procedure, thereby introducing what is known as a mapping bias. Realignment of all raw reads was therefore performed using a reference genome that was masked at each of the 3734 txSNPs, referred to as the masked alignment. An aeQTL analysis was performed using both alignments, discovering 42 and 34 aeQTLs in the unmasked and masked alignments respectively (Figure 3 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}). However, calculation of overall reference allele fraction in both the masked and unmasked data set showed that the reference allele was particularly favored when using an un-masked reference genome (Mean 0.515±0.14). Using a masked reference genome during the alignment shrinks the effect (Mean 0.505±0.14), [Fig 2C](#pone.0217765.g002){ref-type="fig"}, Table S2 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}, which is consistent with results by others \[[@pone.0217765.ref012]\]. This finding justified the exclusive use of the masked alignment for all subsequent analyses. An additional investigation of mapping bias for the significant aeQTLs showed no significant effect on the result. Generated QQ-plots and plots for inspection of heteroscedasticity at the level of each significant aeQTL confirmed the usability of a linear regression model, Figs 1 to 52 in [S2 File](#pone.0217765.s002){ref-type="supplementary-material"}.

Analysis of QTLs in brain tissue reveals novel causal risk genes for schizophrenia {#sec015}
----------------------------------------------------------------------------------

Of the 340 proximal genes analyzed, we found evidence of risk-SNP mediated gene expression modulation for 30 genes, located proximal to 21 SZ risk-SNPs. This difference was a consequence of 9 risk-SNPs having aeQTL effects with more than one gene (see [Fig 3](#pone.0217765.g003){ref-type="fig"}), a concept which is in line with previous eQTL findings \[[@pone.0217765.ref013]\]. We found that 4 SNPs and 12 gene-SNP pairs did not previously have evidence of missense proxies or brain eQTL (bold text, [Table 1](#pone.0217765.t001){ref-type="table"}). [Fig 4](#pone.0217765.g004){ref-type="fig"} shows an overview of previously found gene-level brain eQTLs \[[@pone.0217765.ref001], [@pone.0217765.ref006], [@pone.0217765.ref007]\] and coding evidence \[[@pone.0217765.ref001]\] proximal to the 108 SZ risk loci.

![Plot of aeQTL effects in the genes surrounding the *rs2905426* risk-SNP.\
Each box in the annotationTrack shows one gene. Each dot shows one analyzable txSNP. The X-position of the dot indicates location in gene, and the Y-position indicates the aeQTL significance levels as--log10(P). The horizontal line indicates txSNP level significance at FDR5% (P = 0.0030). The color of each dot indicates effect-direction, red corresponds to increased fraction of ref-allele containing reads. The intensity of the color corresponds to the number of samples analyzable for the given txSNP, with 100 or more samples shown as fully saturated color. The GeneRegionTrack indicates the location of all the genes of interest surround this risk-SNP. The risk-SNP is indicated as a vertical red line. The top track contains the name of the gene as well as the P-value of the strongest associated txSNP.](pone.0217765.g003){#pone.0217765.g003}

![Overview comparing gene-level eQTL and aeQTL findings for the SZ risk-SNPs under analysis.\
Each bar corresponds to a single risk-SNP and the height of the bar shows the number of genes within 200kb. The color code indicates which of these genes have mechanistic evidence, either from previous or current work. Mechanistic evidence is here defined as either missense SNPs in proxy with the GWAS risk SNPs, gene-level eQTL effects, or aeQTL effects. Note that all 124 risk-SNPs in the 108 loci are shown, including 13 risk-SNPs with no genes within 200kb.](pone.0217765.g004){#pone.0217765.g004}
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###### Overview of aeQTL findings in DLPFC tissue.

![](pone.0217765.t001){#pone.0217765.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP                              Pos         Gene               Dist (Kb)   Dist rank   Ref/Alt   Direction aeQTL/eQTL   aeQTL P      eQTL P (7)    Additional gene-SNP evidence                                                                                                 tx-SNPs   Reads   Individuals per aeQTL group   Protein                                            Tissue
  -------------------------------- ----------- ------------------ ----------- ----------- --------- ---------------------- ------------ ------------- ---------------------------------------------------------------------------------------------------------------------------- --------- ------- ----------------------------- -------------------------------------------------- --------
  **rs11210892**                   chr1:44     **PTPRF**          12          1           **G**/A   down/-                 1.40e-06     0.93          \-                                                                                                                           17        1500    129/287/121                   Protein Tyrosine Phosphatase                       DLPFC

  rs140505938                      chr1:150    VPS45              -8          1           **C**/T   up/down                0.0018       0.00249       [Js (P = 1.9e-16)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs140505938:150031490:C:T/er24106)                       5         87      19/74/21                      Vacuolar Protein Sorting 45 Homolog                DLPFC

                                               **ANP32e**         -160        8           **C**/T   down/-                 7.20e-10     0.337                                                                                                                                      8         670     49/311/54                     LANP-L                                             DLPFC

  rs6670165                        chr1:177    BRINP2             29          1           C/**T**   down/-                 7.00e-13     0.0989        [Js (P = 2.2e-8)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs6670165:177280121:C:T/e86307)                           4         1600    76/250/88                     BRINP2                                             DLPFC

  rs7523273                        chr1:208    CD46               8           1           **A**/G   up/up                  1.00e-15     1.1e-33       [Js (P = 9.2e-38)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs7523273:207977083:A:G/e98086)                          9         250     137/109/118                   CD46                                               DLPFC

  rs6434928                        chr2:198    HSPD1              -47         3           **G**/A   down/-                 0.00018      0.3           [Js (P = 3.3-14)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs6434928:198304577:G:A/er60573)                          6         260     136/186/119                   Chaperonin 60                                      DLPFC

                                               HSPD1              -47         3           **G**/A   down/-                 1.50e-05     0.76                                                                                                                                       6         370     70/147/68                     \-                                                 HIPPO

                                               **HSPe1-MOB4**     -60         4           **G**/A   up/-                   5.10e-06     0.358         \-                                                                                                                           9         51      121/128/113                   Chap. 10, Mps One Binder Kinase Activator-Like 3   DLPFC

  rs2535627                        chr3:53     **SPCS1**          103         6           **T**/C   down/-                 0.00000003   0.142         \-                                                                                                                           3         230     116/119/98                    Signal Peptidase Complex Subunit 1                 DLPFC

                                               NeK4               40          4           **T**/C   up/up                  1.30e-05     0.0000015     [Js (P = 1.3e-8)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs2535627/er75865)                                        9         44      134/153/128                   NIMA Related Kinase 4                              DLPFC

  rs9841616 (chr3_180594593_I)     chr3:181    **DNAJC19**        -107        2           **D**/I   up/-                   0.0014       0.926         \-                                                                                                                           2         54      113/17/124                    Mito. Inner membr. translocase subunit TIM14       DLPFC

  rs10043984                       chr5:138    FAM53C             27          2           C/**T**   down/-                 0.00046      0.432         [Js (P = 5.6e-06)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs10043984:137712121:C:T/er118094)                       9         99      94/239/82                     FAM53C                                             DLPFC

  rs111896713 (chr5_140143664_I)   chr5:140    ZMAT2              58          2           D/**I**   down/up                5.60e-20     0.000000197   [Js (P = 2.2e-8)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs111896713:140143664:C:CATTGAAAGAAA/e358075)             2         250     155/32/129                    Zinc finger matrin-type protein 2                  DLPFC

                                               ZMAT2              58          2           D/**I**   down/down              2.20e-08     0.048                                                                                                                                      2         180     94/30/73                      Zinc finger matrin-type protein 2                  HIPPO

                                               IK                 102         7           D/**I**   down/up                0.0005       0.012         \-                                                                                                                           5         150     91/118/70                     Cytokine IK                                        DLPFC

                                               NDUFA2             116         8           D/**I**   down/down              4.20e-11     0.00596       Rg (P = 2.2e-5)                                                                                                              2         76      129/77/96                     Ubiquinone Oxidoreductase Sub-u. A2                DLPFC

  **rs1339227**                    chr6:73     **RIMS1**          43          1           **C**/T   down/-                 0.0013       0.128         \-                                                                                                                           21        440     120/338/103                   Reg. Synaptic Membr. exocytosis 1                  DLPFC

  rs11191419                       chr10:105   AS3MT-BORCS7       -2          1           **T**/A   up/up                  6.40e-20     1.88e-25      [Rg (P = 2.6e-5), Js (P = 2.0e-59)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs11191419:104612335:T:A/er209104)      20        130     140/132/143                   Arsenite Methyltransferase                         DLPFC

                                               AS3MT-BORCS7       -2          1           **T**/A   up/up                  4.90e-08     5.10e-14                                                                                                                                   20        99      84/55/84                      Arsenite Methyltransferase                         HIPPO

  rs55833108                       chr10:105   AS3MT-BORCS7       80          2           G/**T**   down/-                 0.0022       0.0684        \-                                                                                                                           20        130     38/336/41                     Arsenite Methyltransferase                         DLPFC

  rs10791097                       chr11:131   SNX19              -28         1           **T**/G   up/up                  9.50e-08     2.3e-10       [Js (P = 3.2e-29)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs10791097:130718630:T:G/chr11:130749607-130773149(*))   44        710     146/293/134                   Sorting Nexin 19                                   DLPFC

                                               SNX19              -28         1           T/G       up/up                  1.70e-06     0.024                                                                                                                                      44        1000    93/196/86                     Sorting Nexin 19                                   HIPPO

  **rs12826178**                   chr12:58    **LRP1**           16          4           **G**/T   down/-                 3.20e-05     0.383         \-                                                                                                                           32        130     24/413/23                     LDL Receptor Related Protein 1                     DLPFC

  rs12887734                       chr14:104   APOPT1             0           1           G/**T**   down/down              5.40e-44     1.12e-10      [Js (P = 3.0e-22)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs12887734:104046834:G:T/e850242)                        8         6300    119/57/109                    Apoptogenic 1                                      DLPFC

                                               **CKB**            59          4           G/**T**   down/-                 2.20e-07     0.617         \-                                                                                                                           3         9200    66/249/65                     Creatine Kinase B                                  DLPFC

                                               **PPP1R13B**       -153        8           G/**T**   down/down              0.0006       0.0166        \-                                                                                                                           9         40      38/107/37                     Phosphatase 1 Regulatory Sub-u. 13B                DLPFC

  **rs56205728**                   chr15:41    **BUB1B-PAK6**     0           1           G/**A**   down/down              0.0014       0.049         \-                                                                                                                           38        1200    112/329/98                    Mitotic checkpoint ser/ Ser/thr-protein kinase     DLPFC

  rs4702                           chr15:91    FURIN              0           1           **G**/A   down/down              2.70e-11     0.00175       Fg (P = 1.0e-6)                                                                                                              10        64      133/207/135                   Membrane Associated Receptor Prot.                 DLPFC

  rs12691307                       chr16:30    FAM57B             -96         12          **A**/G   up/up                  1.70e-07     0.00815       [Js (P = 5.1e-6)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs12691307:29939877:A:G/chr16:30037091-30037929(*))       4         310     125/157/140                   FP1188                                             DLPFC

  rs8044995                        chr16:68    PRMT7              -156        7           G/**A**   down/down              0.00081      1.96e-05      [Rg (P = 2.2e-5), Js (P = 1.0e-10)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs8044995/chr16:68345003-68349799(*))   9         530     82/265/95                     Protein Arginine Methyltransferase 7               DLPFC

                                               **LCAT-SLC12A4**   191         9           G/**A**   down/-                 0.00039      0.358         \-                                                                                                                           11        18      53/98/66                      Lecithin-Cholesterol Acyltransferase, Solute\      DLPFC
                                                                                                                                                                                                                                                                                                                                   Carrier Family 12 Member 4                         

  rs8082590                        chr17:18    TOM1L2             186         8           **G**/A   down/down              6.70e-12     0.00161       [Js (P = 3.8e-05)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs8082590:17958402:G:A/chr17:17788083-17801909(*))       24        390     133/139/146                   Target Of Membrane Trafficking Prot.               DLPFC

  rs2905426                        chr19:19    GATAD2A            -98         4           **G**/T   down/down              9.70e-05     1.82e-10      [Js (P = 1.1e-8)](http://eqtl.brainseq.org/phase1/eqtl/stats/dlpfc/rs2905426:19478022:G:T/er339847)                          15        82      127/147/133                   GATA Zinc Finger Domain Contain. 2A                DLPFC

                                               **HAPLN4**         109         5           **G**/T   up/-                   6.70e-19     0.979         \-                                                                                                                           12        240     100/153/102                   Brain Link Protein 2                               DLPFC
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All pairs of risk-SNPs and genes at 200 kb range were investigated and are included in the table if they have a FDR5% significant aeQTL effect (P \< 0.0025). The risk-SNPs are highlighted in bold when no other functional evidence exists for that loci, i.e. no coding proxy (1), no gene-level brain eQTL (1,6,7) and no splice-level brain eQTL (7). Similarly, the genesymbol is highlighted in bold when no other functional evidence exists for that gene-SNP pair (same criteria). Pos: position. Dist: distance in kb. Dist rank: rank of gene by proximity to risk-SNP. Ref/Alt: reference and alternative allele. Bold indicates the SZ-risk increasing allele. Dir: gene expression direction induced by risk allele, indicated both for eQTL and aeQTL, when significant. txSNP: count of transcribed SNPs in gene with at least one heterozygote sample. Reads: The mean read coverage of the individuals for the txSNPs with highest coverage. N group: count of samples with at least one heterozygous txSNP stratified by risk-SNP groups (as defined in [Fig 1A](#pone.0217765.g001){ref-type="fig"}). Further gene-SNP evidence: Js = Jaffe-splice-QTL, Fg = Fromer-gene-eQTL (CommondMind), Rc = Ripke-Coding, Rg = Ripke-gene-eQTL. Tissue: DLPFC, dorso-lateral pre-frontal cortex. HIPPO: comparative analysis in hippocampus data.

The main goal of this analysis was to introduce the novel concept of aeQTL risk-SNP analysis and show how it adds to the eQTL method by increasing new QTL discoveries. Of the 34 significant aeQTLs in this analysis, 30 unique SNP-gene pairs were discovered by aeQTL at FDR5%, 10 SNP-gene pairs had FDR5%-significant direction-consistent evidence from both eQTL and aeQTL, and 6 additional FDR5%-significant aeQTL associations had nominal eQTL significance (P\<0.05) in the same direction. These counts are further detailed in [Table 1](#pone.0217765.t001){ref-type="table"} in the column "direction aeQTL/eQTL", wherein pairwise significance and direction are indicated for every SNP-gene pair that had FDR5% significant aeQTL effects. Obversely, 55 tested SNP-gene pairs were found as eQTL but not aeQTL.

In the two investigated brain regions, we found that the majority of expression association evidence was found in DLPFC, and not confirmed in hippocampus. Of the 30 SNP-gene pairs observed by aeQTL, 4 were replicated in the smaller set of hippocampus data. Since the DLPFC data set was slightly larger than the hippocampus (n = 680 vs n = 421), we repeated this analysis with a downsampling of the DLPFC, still obtaining overrepresentation of DLPFC findings (Figure 4 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}). There were not enough fetal samples to conduct a separate analysis to highlight developmental genes, but including the additional 58 fetal samples in the cohort to the main analysis can suggest genes more sensitive to developmental changes. We found 11 other associations, 8 in DLPFC and 3 in hippocampus, all borderline significant except *CENPM* (p = 2.4e-12) and *EFTUD1P1* (p = 2.8e-05) for eQTL, and the *"GNL3*, *SNORD19*, *SNORD69*, *SNORD19B"* region (7e-04) for aeQTL. The inclusion of the 58 fetal samples also resulted in a loss of 7 borderline significant associations, 5 in DLPFC and 2 in hippocampus (Tables S5 and S6 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}). Overall, these findings indicate that novel gene associations can be established with aeQTL, that there is overlap between this method and the eQTL method, and that DLPFC tissue contains more transcriptomic associations of SZ risk-SNPs than hippocampal tissue.

Detailed investigation of each txSNP reveals possible splice effects {#sec016}
--------------------------------------------------------------------

Although each gene only has a limited amount of analyzable txSNPs, we explored if the aeQTL-differences in the txSNP of each gene could nonetheless be used to describe possible splice effects. We expect neighboring txSNPs within the same gene should show similar effect-size and direction, if they are not affected by splice effects. Conversely, splice-effects may be observable as differences in effect-size and direction. We therefore investigated each txSNP in the genes of interest, illustrated by [Fig 3](#pone.0217765.g003){ref-type="fig"} that shows the example of HAPLN4 (all others are available as Figures 1 to 65 in [S3 File](#pone.0217765.s003){ref-type="supplementary-material"}). While the HAPLN4 region showed an example of consistent unidirectional aeQTL effects from all txSNP in a single gene, this was not always the case: the txSNP-level plotting revealed a number of cases with non-significant gene-level metrics, but strong independent aeQTL-effects from some txSNPs. Taking the increased multiple-testing burden into account we found 156 txSNPs with aeQTL effect significant at FDR5% level (Tables S3 and S4 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}), associating 18 more risk-SNPs not found by aeQTL at the gene level. The txSNP aeQTL approach could conceivably be used for a similar purpose as splice eQTL investigations described elsewhere \[[@pone.0217765.ref007]\].

Interaction analysis provides possible explanations of discrepancy between eQTL and aeQTL {#sec017}
-----------------------------------------------------------------------------------------

To study the discrepancies between eQTL and aeQTL and attempt to discover their causes we re-calculated all QTLs using covariates likely to have influence. These included RNA-integrity number (RIN), age, sex, diagnosis and smoking status. Particularly for RIN-value we wished to test the hypothesis that aeQTL was less affected by changes in RNA quality. While attractive as an example case, the systematic analysis did not completely support that RIN value is a main covariate for all risk-SNP gene pairs; using a binary cutoff at RIN 8, eQTL analysis showed 5 pairs with interaction effects, in aeQTL analysis only 1 pair did (Figure 5 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}). Some examples of this were found, including the gene *LRRN3* and risk-SNP *rs13240464* which showed significant interactions with RIN-values(P~interaction~ = 1.36e-04), raising an uncertainty regarding the main effect of the eQTL at lower RNA qualities, as the low RIN samples show a significant eQTL (P = 0.00049) (Figure 6A in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}): The aeQTL analysis for the same risk-SNP gene pair showed no significance interaction (P~interaction~ = 0.37), and showed no significant aeQTL for low RIN-value (P = 0.51) (Figure 6B in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}). In Figure 7 in [S1 File](#pone.0217765.s001){ref-type="supplementary-material"}, eQTL appears more sensitive to RIN covariates than aeQTL, and we can also see that addition of more covariates has a higher effect on eQTL. In particular, including genetic and expression PCs changes the p-value more than for RIN, which suggests that for brain tissue more covariates than the RIN value is likely to be important. The use of aeQTL can be used to partially circumvent these covariates, and be a good compliment to standard eQTL analysis. Likewise, the remaining covariate analyses gave some possible explanatory examples, but were not able discover a fundamental explanation for discrepancies.

Discussion {#sec018}
==========

The eQTL approach is an established tool to link non-transcribed GWAS risk-SNPs with transcribed proximal genes. In this paper, we explore and compare with the possibly complimentary aeQTL approach. This method is inspired by previous microarray-based studies, in which phasing of genotypes is used to link txSNPs with a non-transcribed (risk) SNP \[[@pone.0217765.ref008]\]. We here refer to this linking as aeQTL analysis, and describe a study were the method is adapted to RNA-sequencing data, enabling the systematic uncovering of previously concealed expression-modulating effects from all known SZ GWAS-risk SNPs. The overall goal is to compare established (eQTL) and alternative tools (aeQTL) for functional linking of GWAS risk-SNPs and genes.

Findings {#sec019}
--------

In the previous brain eQTL analysis it was shown that 30 loci have gene-level eQTL and an additional 21 loci had splice- or exon-eQTL \[[@pone.0217765.ref007]\]. In this study, 16 and 6 of those loci were also identified using the gene-level and exon-level aeQTL approach, respectively, but not necessarily pointing towards the same gene. We speculate that these discrepancies may arise from the complexity of transcriptional regulation, such as for example how feedback loops may work to mask one method but not the other. While the goal of both eQTL and aeQTL is the same--to functionally investigate links between SNPs and genes--the approach is different. Clearly, the eQTL approach has potentially greater resolution because it does not require an expressed heterozygous SNP, as the comparison data show, but the aeQTL strategy may uncover additional genetic associations missed in the eQTL analysis. Overall, we found that 30 genes proximal to 21 known SZ risk-SNPs showed evidence of risk-SNP mediated allelic expression modulation (aeQTL).

Several of the findings emphasize already known links to brain functioning and development. In addition to eQTL-discoverable genes such as *CHRNA5*, *MAPK3* and *AS3MT* \[[@pone.0217765.ref014]--[@pone.0217765.ref016]\], these include the *HAPLN4* (Brain Link Protein 2), and the *RIMS1* (Regulating Synaptic Membrane Exocytosis 1). Several additional findings in [Table 1](#pone.0217765.t001){ref-type="table"} are of interest to follow-up with further studies: one signaling receptor, peptidase, translocase, transferase and two chaperonins together with several kinases and phosphatases. Systematic gene set enrichment analysis has already been performed in the initial GWAS as well as follow-up studies \[[@pone.0217765.ref001]\]; however, the main point to underscore is that such analysis often make the mistaken assumption that the closest gene is the mechanistically relevant gene. As shown in the *dist-rank* column of [Table 1](#pone.0217765.t001){ref-type="table"}, and also evidenced by similar findings elsewhere \[[@pone.0217765.ref017]\], the closest gene is often not the functionally relevant gene. This was the case for 39 of 58 reported SNP-gene pairs in this analysis, which illustrates the strength of strengthening the use of functional genetics methods, such as eQTL and aeQTL, in order to arrive at more solid knowledge of *risk-genes* rather than just risk-SNPs and the genes next to them. Future studies might be further improved by combining this approach with colocalization analysis.

Challenges of using the aeQTL method {#sec020}
------------------------------------

The first challenge is that at least some samples need to be heterozygous for one or more txSNPs to produce a reliable regression model. A second problem is that some deviation from 1:1 may be ascribed to a mapping bias. Thirdly, to link the risk SNP with an AI event in the most effective manner, it is necessary to know the phase of the alleles, a challenge for which several solutions exists. In this paper, we present and apply calculation pipelines that address these three issues, and discuss what limitations remain for each.

To measure allelic imbalance, it is a requirement that a gene have one or more txSNPs that are heterozygous. This problem diminishes with larger sample sizes, as well as longer and less conserved genes. This problem was overcome in part by the creation of a system that summarized consecutive txSNPs within a gene evaluating their joint AI. This enabled us to investigate a total of 340 genes, thereby largely addressing the problem of lack of heterozygous txSNPs ([Fig 2D](#pone.0217765.g002){ref-type="fig"}).

The problem of mapping bias appears when RNA-seq reads containing the reference allele have larger likelihood of successful mapping, than those containing the alternative allele. By looking at the overall mean of all SNPs we observed that the average ref-allele fraction of all SNPs was different from the expected value of 0.5, indicating a modest but non-ignorable bias. To address this, we re-aligned the RNA-sequencing data using a version of the reference genome that was N-masked at all common SNP locations; this altered the ref-allele frequency to mean 0.505±0.14, reinforcing the notation that mapping bias is a potential issue in AI-calculations (see [Fig 2C](#pone.0217765.g002){ref-type="fig"}). Even if mapping bias is detrimental when looking at the allele frequency for only one individual, the problem is reduced if the bias is spread equally over all genotype groups i.e., the ref-allele is equally present over all genotype groups. Even though the summarization step is advantageous to increase the pool of heterozygote samples, there is a risk when using fraction mean that some reads overlap multiple txSNPs. Other approaches to this have been developed, include handling of the potential for very proximal txSNPs \[[@pone.0217765.ref018]\].

This situation is nevertheless not unique to aeQTL, as there exist a similar concern in eQTL studies, where RNA sequencing mapping bias or microarray allele specific hybridization may have an impact on the result. To test for any impact by mapping bias on our aeQTL after masking we performed a linear regression using the ref-allele fraction for each genotype group. Even if we could see remains of mapping bias for certain genes, none showed any significant relationship to the genotype group, supporting that our aeQTLs found were real and not due to technical artifacts (Supplementary Figures 1 to 52 in [S2 File](#pone.0217765.s002){ref-type="supplementary-material"}).

Finally, to link allelic imbalance with a (non-transcribed) risk SNP, phase has to be known in order to match the alleles of the txSNPs with the alleles of the risk SNP. The allele fraction calculated could suffer from uncertainty in phase generation, but this will be randomly distributed, introducing noise but not biasing the results. Other methods have been explored for doing this, by assuming that the AI for the heterozygous risk-SNPs should have a higher variance than the homozygote risk-SNPs \[[@pone.0217765.ref019]\], but we found the statistical power of such analysis is drastically reduced, and we could not find any associations in our data (Figures 1 to 52 in [S2 File](#pone.0217765.s002){ref-type="supplementary-material"}). From this we conclude that phasing-based methods are the stronger for linking txSNPs and non-transcribed SNPs.

Functionality for using these approaches has been implemented into the *AllelicImbalance* package, which is available in the Bioconductor repository \[[@pone.0217765.ref011]\].

Contrary to our initial hypothesis regarding the quality of samples from brain tissue and its confounding effects on eQTL, our results indicate a relatively little impact of RIN. This is in the same line as previous research where genotype did not significantly associate with RIN \[[@pone.0217765.ref020]\]. Recent work has demonstrated that RIN is not an adequate approach to RNA quality correction and that other methods may be indicated to further resolve this issue \[[@pone.0217765.ref020]\]. The increase of QTLs by using allelic imbalance information is more likely coming from its ability to remove the variation caused by trans-regulation of transcription.

Conclusion {#sec021}
==========

We have compared eQTL and aeQTL strategies in the context of human brain and schizophrenia risk SNPs. The main conceptual points we pursued in this study are i) the description of methodology for linking allelic imbalance with non-transcribed risk-SNPs in RNA-sequencing analysis and the ii) application of this methodology to a brain-tissue biobank. Overall, we find that the two methodologies have an overlap of significant QTLs, but also some differences where each method can find additional QTLs. We have discussed possible explanations for the differences, such as heterozygozity, read-depth, phasing, sample size and trans-regulation. However, further research will be required for determining the exact mechanism behind the differences. Taken together we believe these findings will have implications for how we use functional genetics to link GWAS risk-SNPs with genes.
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